CAG-GFP AAV (Serotype MyoAAV4E)

CAG-GFP AAV (Serotype MyoAAV4E) drives sustained expression of the GFP (green fluorescent protein) reporter gene in muscle cells. The MyoAAV4E viral particles are engineered for enhanced transduction efficiency, ensuring effective entry into muscle cells and robust GFP gene expression. Using AAV as a viral vector offers several advantages, such as low immunogenicity and long-term persistence in host cells without integration into the host genome, thus minimizing the risk of insertional mutagenesis. Furthermore, AAV vectors can be produced in large quantities with high purity, making them suitable for therapeutic applications.

In terms of applications, CAG-GFP AAV (Serotype MyoAAV4E) is a valuable tool for studying muscle development, regeneration, and various muscle diseases. The GFP reporter gene allows for real-time visualization of muscle cell activity and gene expression. Researchers can use fluorescence microscopy to track dynamic changes in muscle cells, significantly enhancing our understanding of muscle physiology and pathology. This vector can also be used to develop gene therapies for muscle diseases such as Duchenne muscular dystrophy (DMD) and spinal muscular atrophy (SMA). Additionally, this vector facilitates gene function studies through loss-of-function or gain-of-function experiments in muscle cells, allowing researchers to gain deeper insights into the role of specific genes in muscle biology.